The Astrazeneka Company launched the country’s first production of the innovative target drug for treatment of lung cancer in the “Vorsino” Industrial Park in the Kaluga Region. The volume of investments in the new line was more than 700 mln rubles, as reported by the press services of the Kaluga Region’s Government.
Swedish-British AstraZeneca pharmaceutical company will sign a special investment contract with Kaluga Region to localise drug production at Kaluga plant. The Governor of Kaluga Region Anatoly Artamonov announced the company’s plans to sign the document in TASS press centre today. AstraZeneca opened the plant in Kaluga region in October 2015, and this is the only company’s manufacturing facility in Russia. Over $224 mln was invested in its creation. By 2017, the facility will reach design capacity and produce up to 850 mln pills or 40 mln packs annually. In 2017, the factory is going to move to a full production cycle — from creation of formulated products to packaging, as well as to produce about 30 medicines, including drugs for cancer, cardiovascular and respiratory diseases, mental and other disorders.
AstraZeneca, British-Swedish multinational pharmaceutical and biologics company, started commercial production at its first plant in Russia in Vorsino Industrial Park, Kaluga Oblast.
Today is the launch of the first phase, including packaging and quality control. The plant is planned to start full-cycle production from dosage form development to packaging in 2017.
Today, AstraZeneca announced the opening of its own local production facility in Russia in the Kaluga Oblast. The total amount of investment in the creation of a new production facility is estimated at over 224 million US dollars. The Kaluga plant will create jobs for approximately 200 specialists.
The beginning of commercial production is scheduled for the 1st quarter of 2016, the transition to full capacity operation is planned for 2017. The annual capacity of the facility will amount to approximately 40 million packages or 850 million tablets. The plant will produce approximately 30 AstraZeneca branded innovative pharmaceutical products.
"Russia is one of the priority markets for AstraZeneca company. We aim to make a significant contribution to the innovative pharmaceutical industry in the country, thus ensuring the availability of innovative medicines for Russian patients," said the representative of the company.
The opening ceremony was attended by Pascal Sorio, CEO of AstraZeneca, Anatoly Artamonov, the Governor of the Kaluga Oblast, Alexey Repik, the President of Delovaya Rossiya All-Russia Public Organization, Igor Khagramanyan, the First Deputy Minister of Health of the Russian Federation, as well as Peter Eriksson, the Extraordinary and Plenipotentiary Ambassador of the Kingdom of Sweden to the Russian Federation, and sir Tim Barrow, the Extraordinary and Plenipotentiary Ambassador of the United kingdom to the Russian Federation.
Pascal Sorio, CEO of AstraZeneca: "The establishment of our state-of-the-art enterprise will increase the availability of AstraZeneca innovative medicines for Russian patients. The localization of production confirms our long-term development strategy in Russia, along with the growth of investment in clinical trials and research projects in this important market for us".
The Russian branch of AstraZeneca meets all international standards, including GMP, occupational health and safety requirements, environmental protection requirements, as well as lean production requirements. All production operations are carried out in compliance with the ethical rules and principles.
UK-based pharmaceutical company, AstraZeneca, is to launch a new manufacturing facility in Kaluga regions
The firm intends to launch the facility in the second half of the year, with the first phase involving the packaging part of production. Astra Zeneca has invested USD 223 million and is set to produce 30 innovative drugs, including drugs within the cardiology, oncology, psychiatry, gastroenterology and pulmonology therapeutic areas.
The new location is part of the company's strategy to establish full-cycle production in Russia in order to strengthen its position in the market.
The British-Swedish pharmaceutical giant AstraZeneca receives a licence to manufacture medicines in Russia. When it reaches full capacity, its plant at the Vorsino industrial park in the Kaluga Region will be able to produce 25 m packs of medicines a year. It is planned to start production this year.
The British-Swedish pharmaceutical company AstraZeneca has been granted a licence to manufacture medicines in Russia, the company’s press service announced.
Earlier AstraZeneca has already built a medicine packaging and engineering building at the Vorsino industrial park in the Kaluga Region. Start-up is planned for the second half of this year. The Company intends to produce 25 million medicine packs in a year hear.
This is one of the first bio-pharmaceutical companies to announce construction of full cycle production in Russia. The firm announced its intention back in 2011, when it chose the site for developing production in the Kaluga Region. Declared investment is USD 223 m.
At Vorsino, the company will produce up to 30 innovative medicines for treating socially significant diseases in such spheres as cardiology, oncology, psychiatry, gastroenterology and pulmonology, its press service specified.
In addition, the company intends to cooperate with Russian scientific centres in developing new medicines and improving those already in production. The first agreement was already concluded this year with Park of Active Molecules in Obninsk.
Astra Zeneca is also one of the biggest production units of the Kaluga bio-pharmaceutical cluster. There are currently 50 Russian and foreign pharma companies registered in the Region, including the Danish company Novo Norgisk, the Serbian company Hemofarm, the Russian Nearmedic Plus and others that are already operating.
As its government announced, the Kaluga Region, as the government of the Region announced, intends to occupy up to 12% of the domestic market for medicines.
On May 12, the biopharmaceutical company AstraZeneca announced the launch of a new project within the scope of the “Open Innovations” initiative, aimed at the development of scientific research potential in Russia. The project will be implemented in partnership with the innovative core of the Kaluga pharmaceutical cluster Active Molecules’ Park Competence Alliance (AMP) and the AMP Scientific Research Center.
Within the scope of the “Open Innovations” initiative, AMP scientists will be able to participate in pre-clinical studies of an AstraZeneca molecule that has potential in the treatment of malignant tumors. AstraZeneca specialists will also share their knowledge and expertise in order to ensure successful development of this molecule in potential new medicines. The financial terms of the collaboration have not been disclosed.
Ajay Gautam, Executive Director and Head of Collaborations for Asia & Emerging Markets, AstraZeneca: “Russia is a priority developing market with a rich scientific base. Our cooperation with the AMP Scientific Research Center is aimed at the development and research of potential innovative drugs that can have significant impact on the health of patients. ‘Open Innovations’ is a project created to expand scientific horizons and speed up the development and creation of innovative medicine in areas of unmet medical needs. We are very happy that ‘Open Innovations’ has been launched in Russia, and that we are working with AMP Scientific Research Center and Medbiopharm. This may become the foundation for developing new cancer drugs.”
Company's website: www.astrazeneca.com
T: +44 2076048000
Public company (NYSE: AZN)
Contact: Pascal Soriot, Director General
AstraZeneca PLC is an Anglo-Swedish pharmaceutical company incorporated in the UK. As of 2014, it is the tenth largest company in the world by sales of prescription drugs. AstraZeneca's product portfolio includes medication for various therapeutic areas, such as cardiology, pulmonology, oncology, neurology, gastroenterology, psychiatry and infectious diseases. The company was formed in 1999 through the merger of the Swedish and British Astra AB Zeneca Group (formed as a result of separating the pharmaceutical business of Imperial Chemical Industries in 1993).